• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
Shop

Republican Lawmakers Introduce New Bill for Psychedelic Therapy

Jason Najum by Jason Najum
June 15, 2023
in Law & Politics
Reading Time: 2 mins read
A A
Republican Lawmakers Introduce New Bill for Psychedelic Therapy

Republican lawmakers pushing for psychedelic medicine legislation

Conservative Republican politicians standing outside of Congress, holding a press conference, advocating for the legal use of psychedelic medicine.

The times are definitely changing.

And so is public sentiment and the taboo around psychedelics.

On Wednesday, Republican lawmakers and former military veterans spoke to the public about the benefits of psychedelic medicine and the urgent need to give soldiers access to these therapies.

[bsa_pro_ad_space id=2]
ADVERTISEMENT

Rep. Dan Crenshaw (R-TX), himself a wounded military veteran, has been pushing for access to psychedelics, having witnessed first-hand how it’s helped fellow service members. Crenshaw is leading a piece of legislation called the “Douglas ‘Mike’ Day Psychedelic Therapy to Save Lives Act of 2023,” named after a Navy SEAL who died this year.

Continue on your trip...

Psylutions and the DEA

US Congress Adds Psychedelics Studies to Defense Bill

Enveric Granted US Patent for Psilocybin Derivatives

The bill, if passed, would devote $75 million in federal grant money to research into psychedelics therapy, focused on health conditions faced by veterans and active service members.

 

I’m live now unveiling the Douglas ‘Mike’ Day Psychedelic Therapy To Save Lives Act: https://t.co/LxuJeHAOoA pic.twitter.com/qpkKuTkKE5

— Rep. Dan Crenshaw (@RepDanCrenshaw) June 14, 2023

The Republican congressman was joined by Rep. Morgan Luttrell (R-TX), a military veteran who went abroad for psychedelic-assisted treatment with ibogaine and 5-MeO-DMT. The veteran shared how psychedelics changed his life and was “one of the greatest things that ever happened to me.”

“If you find yourself in a place that you were lost, and no other modalities have worked, this could possibly be that tool,”

“And I can honestly stand in front of all of you and the American public and say I was reborn. This changed my life. It saved my marriage. It is one of the greatest things that ever happened to me.”

Buy Verified Lasix

The bill would allocate funds to funding clinical trials into psychelics like psilocybin, ibogaine, MDMA and 5–MeO–DMT.

“I’m once again calling on Congress to use this year’s NDAA to direct the Secretary of Defense to provide grants for further research into the use of psychedelics to treat PTSD and TBI in our active-duty service members,” Rep. Dan Crenshaw said.

“Why am I pushing for this? Because it works. And as Mike’s widow Brenda would attest to, it could have saved Mike’s life,” Rep. Crenshaw said, referring to Mike Day – the namesake of the bill. Day served 21 years as a Navy SEAL, and tragically took his own life earlier this year.

The bill has a broad, bipartisan coalition of co-sponsors including Alexandra Ocasio-Cortez and others.

[bsa_pro_ad_space id=2]
ADVERTISEMENT

Read the full bill here.

And see the press conference below.

 

 

Tags: Decriminalization
Jason Najum

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Next Post
Tripping Without The Trip: Non-Hallucinogenic Psychedelics

New Study: Psychedelics Reopen Social Reward Learning Period

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.